| Moderate risk | High risk | Very high risk | p |
---|---|---|---|---|
Number of subjects | 2,819 | 98,781 | 372,140 | Â |
Age (years) | 41.6 ± 6.8 | 66.7 ± 13.1 | 70.0 ± 10.2 |  < 0.0001 |
Sex (% male) | 57.6 | 56.5 | 57.2 | 0.0003 |
New diagnoses (%) | 25.3 | 9.9 | 4.9 |  < 0.0001 |
Diabetes duration (years) | 3.0 ± 2.8 | 10.1 ± 8.9 | 12.9 ± 9.5 |  < 0.0001 |
BMI (kg/m2) | 25.6 ± 2.8 | 27.0 ± 4.5 | 30.0 ± 5.5 |  < 0.0001 |
Smokers (%) | 0.0 | 7.6 | 19.2 |  < 0.0001 |
HbA1c (%) | 7.3 ± 1.7 | 7.1 ± 1.3 | 7.2 ± 1.2 | 0.002 |
Blood pressure (mmHg) | ||||
 Systolic | 116.4 ± 11.2 | 130.1 ± 17.0 | 136.5 ± 18.3 |  < 0.0001 |
 Dyastolic | 73.3 ± 7.7 | 75.9 ± 9.2 | 76.9 ± 9.7 |  < 0.0001 |
Total Cholesterol (mg/dl) | 175.1 ± 31.2 | 174.0 ± 33.9 | 167.1 ± 38.8 |  < 0.0001 |
LDL Cholesterol (mg/dl) | 97.8 ± 20.6 | 97.2 ± 27.8 | 91.0 ± 32.7 |  < 0.0001 |
HDL Cholesterol(mg/dl) | 48.5 ± 13.2 | 51.1 ± 13.7 | 48.1 ± 12.7 |  < 0.0001 |
Triglicerides (mg/dl) | 135.8 ± 106.0 | 125.8 ± 78.1 | 141.1 ± 81.6 |  < 0.0001 |
Albuminuria (%) | 0.0 | 0.0 | 39.5 |  < 0.0001 |
eGFR < 30 ml/min/1,73m2 (%) | 0.0 | 0.0 | 8.8 |  < 0.0001 |
Anti-hyperglycemic therapy (%) | ||||
 Metformin | 72.0 | 71.1 | 69.0 |  < 0.0001 |
 DPP4-i | 13.3 | 19.8 | 21.5 |  < 0.0001 |
 Secretagogues | 7.7 | 15.9 | 16.3 |  < 0.0001 |
 Glinides | 1.2 | 3.6 | 3.7 |  < 0.0001 |
 SGLT2-i | 8.5 | 7.7 | 10.0 |  < 0.0001 |
 Glitazones | 3.1 | 4.0 | 4.4 |  < 0.0001 |
 Acarbose | 1.1 | 2.0 | 2.5 |  < 0.0001 |
 GLP1-RA | 2.4 | 3.9 | 6.4 |  < 0.0001 |
 Insulin | 27.6 | 24.4 | 34.5 |  < 0.0001 |
Diabetes treatment scheme (%) | ||||
 Oral Monotherapy | 38.1 | 35.7 | 27.4 |  < 0.0001 |
 Oral Two fold therapy | 19.2 | 23.0 | 21.7 |  < 0.0001 |
 Three or more oral drugs | 3.3 | 6.0 | 6.5 |  < 0.0001 |
 GLP1-RA ± other drugs | 2.4 | 3.9 | 6.4 |  < 0.0001 |
 Insulin + oral drugs | 12.8 | 12.8 | 19.1 |  < 0.0001 |
 Multiple daily insulin injections | 14.5 | 10.9 | 14.2 |  < 0.0001 |
 Anti-hypertensive therapy (%) | 0.0 | 32.9 | 80.4 |  < 0.0001 |
 Lipid-lowering therapy (%) | 0.0 | 18.0 | 72.6 |  < 0.0001 |
 Retinopathy (%) | 0.0 | 0.0 | 26.4 |  < 0.0001 |
  Non proliferative | 0.0 | 0.0 | 19.5 |  |
  Pre-proliferative | 0.0 | 0.0 | 1.9 |  |
  Proliferative | 0.0 | 0.0 | 1.8 |  |
  Laser-treated | 0.0 | 0.0 | 2.6 |  |
  Oftalmopathy | 0.0 | 0.0 | 0.2 |  |
  Blindness | 0.0 | 0.0 | 0.3 |  |
Previous myocardial infarction (%) | 0.0 | 0.0 | 9.5 |  < 0.0001 |
Previous stroke (%) | 0.0 | 0.0 | 3.3 |  < 0.0001 |
Established cardiovascular disease (%) | 0.0 | 0.0 | 18.7 |  < 0.0001 |
Dialisys (%) | 0.0 | 0.0 | 0.3 |  < 0.0001 |